Gaskins Audrey J, Chiu Yu-Han, Williams Paige L, Ford Jennifer B, Toth Thomas L, Hauser Russ, Chavarro Jorge E
Departments of Nutrition,
Departments of Nutrition.
Am J Clin Nutr. 2015 Oct;102(4):943-50. doi: 10.3945/ajcn.115.112185. Epub 2015 Sep 9.
Preconceptional folate and vitamin B-12 have been linked to beneficial reproductive outcomes in both natural pregnancies and those after assisted reproductive technology (ART) treatment.
The objective of the study was to evaluate the associations of serum folate and vitamin B-12 with ART outcomes.
This analysis included a random sample of 100 women (154 ART cycles) participating in a prospective cohort study [Environment and Reproductive Health (EARTH)] at the Massachusetts General Hospital Fertility Center (2007-2013). Serum folate and vitamin B-12 were measured in blood samples collected between days 3 and 9 of treatment. Generalized estimating equations with adjustment for age, BMI, and race were used to evaluate the association of serum folate and vitamin B-12 with ART outcomes.
Women in the highest quartile of serum folate (>26.3 ng/mL) had 1.62 (95% CI: 0.99, 2.65) times the probability of live birth compared with women in the lowest quartile (<16.6 ng/mL). Women in the highest quartile of serum vitamin B-12 (>701 pg/mL) had 2.04 (95% CI: 1.14, 3.62) times the probability of live birth compared with women in the lowest quartile (<439 pg/mL). Suggestive evidence of an interaction was observed; women with serum folate and vitamin B-12 concentrations greater than the median had 1.92 (95% CI: 1.12, 3.29) times the probability of live birth compared with women with folate and vitamin B-12 concentrations less than or equal to the median. This translated into an adjusted difference in live birth rates of 26% (95% CI: 10%, 48%; P = 0.02).
Higher serum concentrations of folate and vitamin B-12 before ART treatment were associated with higher live birth rates among a population exposed to folic acid fortification. This trial was registered at clinicaltrials.gov as NCT00011713.
孕前叶酸和维生素B-12与自然妊娠及辅助生殖技术(ART)治疗后的良好生殖结局相关。
本研究旨在评估血清叶酸和维生素B-12与ART结局之间的关联。
本分析纳入了马萨诸塞州综合医院生育中心(2007 - 2013年)一项前瞻性队列研究[环境与生殖健康(EARTH)]中的100名女性(154个ART周期)的随机样本。在治疗第3至9天采集的血样中测量血清叶酸和维生素B-12。采用对年龄、体重指数和种族进行调整的广义估计方程来评估血清叶酸和维生素B-12与ART结局之间的关联。
血清叶酸处于最高四分位数(>26.3 ng/mL)的女性与最低四分位数(<16.6 ng/mL)的女性相比,活产概率为1.62倍(95%置信区间:0.99,2.65)。血清维生素B-12处于最高四分位数(>701 pg/mL)的女性与最低四分位数(<439 pg/mL)的女性相比,活产概率为2.04倍(95%置信区间:1.14,3.62)。观察到存在交互作用的提示性证据;血清叶酸和维生素B-12浓度高于中位数的女性与叶酸和维生素B-12浓度低于或等于中位数的女性相比,活产概率为1.92倍(95%置信区间:1.12,3.29)。这转化为活产率的调整差异为26%(95%置信区间:10%,48%;P = 0.02)。
在接受叶酸强化的人群中,ART治疗前血清叶酸和维生素B-12浓度较高与较高的活产率相关。本试验在clinicaltrials.gov注册,注册号为NCT00011713。